Custom Search

News

Saturday 01 February 2003

Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy.

By: Hagemeister FB.

Clin Adv Hematol Oncol 2003 Feb;1(2):120-5

Therapy with rituximab is the most important advance in the treatment of lymphomas since the development of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). Rituximab has single-agent activity in all types of B-cell lymphomas, including indolent and aggressive disease. For large-cell lymphomas, rituximab plus chemotherapy represents a significant advance over chemotherapy alone without significant added toxicity. Some studies report positive results using the antibody to treat other lymphomas. CHOP plus rituximab has become the standard of care.

Use of this site is subject to the following terms of use